Gilead Sciences, Inc. (NASDAQ:GILD) shares, rose in value on Friday, April 05, with the stock price down by -0.60% to the previous day’s close as strong demand from buyers drove the stock to $69.13.
Actively observing the price movement in the recent trading, the stock is buoying the session at $69.55. The value of beta (5-year monthly) is 0.20 whereas the PE ratio is 15.35 over 12-month period. Referring to stock’s 52-week performance, its high was $87.86, and the low was $69.39. On the whole, GILD has fluctuated by -4.82% over the past month.
With the market capitalization of Gilead Sciences, Inc. currently standing at about $86.20 billion, investors are eagerly awaiting this quarter’s results, scheduled for Apr 25, 2024 – Apr 29, 2024. The company’s Forward Dividend Ratio is 3.02, with its dividend yield at 4.37%. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be $1.46, which is expected to increase to $1.89 for fiscal year $6.55 and then to about $6.85 by fiscal year 2025. Data indicates that the EPS growth is expected to be 5.60% in 2025, while the next year’s EPS growth is forecast to be 4.60%.
Analysts have estimated the company’s revenue for the quarter at $5.87 billion, with a low estimate of $5.5 billion and a high estimate of $6.25 billion. According to the average forecast, sales growth in current quarter could jump down -7.60%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $25.37 billion, representing an increase of 1.40% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that GILD’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 3.00, with the price of GILD currently trading nearly -5.69% and -6.86% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 27.84, while the 7-day volatility ratio is showing 1.67% which for the 30-day chart, stands at 1.47%. Furthermore, Gilead Sciences, Inc. (GILD)’s beta value is 0.21, and its average true range (ATR) is 1.15.
A comparison of Gilead Sciences, Inc. (GILD) with its peers suggests the former has fared considerably weaker in the market. GILD showed an intraday change of -0.60% in today’s session so far, and over the past year, it shrunk by -15.82%%.
Data on historical trading for Gilead Sciences, Inc. (NASDAQ:GILD) indicates that the trading volumes over the past 10 days have averaged 6.3 million and over the past 3 months, they’ve averaged 7.52 million. According to company’s latest data on outstanding shares, there are 1.25 billion shares outstanding.
Nearly 0.10% of Gilead Sciences, Inc.’s shares belong to company insiders and institutional investors own 85.92% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 19.25 million shares as on Mar 15, 2024, resulting in a short ratio of 2.6. According to the data, the short interest in Gilead Sciences, Inc. (GILD) stood at 1.54% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 19.88 million. The stock has fallen by -14.66% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the GILD stock heading into the next quarter.
